Primary Cytoreductive Surgery Versus Interval Debulking Surgery Following Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer: An Institutional Review

被引:2
|
作者
Ahmad, Zeeshanuddin [1 ]
Jain, Amar [1 ]
Mehta, Nikhil [1 ]
Saldanha, Elroy [1 ]
Patel, Dhruv [1 ]
Desai, Sanjay M. [1 ]
机构
[1] Sri Aurobindo Med Coll & Post Grad Inst, Dept Surg Oncol, Indore, Madhya Pradesh, India
关键词
Epithelial ovarian cancer (EOC); Primary cytoreductive surgery (PCS); Interval debulking surgery (IDS); Neoadjuvant chemotherapy (NACT); ADVANCED-STAGE OVARIAN; EXPLORATORY ANALYSIS; SURVIVAL; CARCINOMA; TIME;
D O I
10.1007/s40944-018-0253-2
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
ObjectiveTo compare theoverall survival of women with advanced-stage EOC treated by PCS versus NACT followed by IDS.Design, Setting, and ParticipantsRetrospective study of women with stage IIB-IVA ovarian carcinoma FIGO staging diagnosed between 2016 and 2018 treated at Department of Surgical Oncology, Sri Aurobindo Medical College and Post Graduate Institute, Indore.ExposuresInitial treatment approach of PCS versus NACT+IDS, examined using an intent-to-treat analysis.ResultsThe median follow-up was 18months (10-36months) in both groups. The median overall survival was 38months in PCS group and 31months in NACT group. Postoperative complications were seen more often in PCS group (11.3%) against 3.33% in NACT group. Patients with residual disease (microscopic and macroscopic residual disease) had poorer prognosis.ConclusionsPrimary cytoreductive surgery is associated with improved survival compared with NACT in otherwise healthy women with bulky epithelial ovarian. The biggest risk associated with the use of NACT is that patients with significant side effects and refractory disease will lose the opportunity for initial surgery. The lower survival in women receiving NACT can be owed to limited performance status in women undergoing NACT.
引用
收藏
页数:4
相关论文
共 50 条
  • [21] Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone?
    Solmaz, Ulas
    Mat, Emre
    Dereli, Murat Levent
    Turan, Volkan
    Peker, Nuri
    Tosun, Gokhan
    Dogan, Askin
    Adiyeke, Mehmet
    Ozdemir, Aykut
    Gungorduk, Kemal
    Sanci, Muzaffer
    Yildirim, Yusuf
    JOURNAL OF BUON, 2015, 20 (03): : 847 - 854
  • [22] Residual tumor and primary debulking surgery vs interval debulking surgery in stage IV epithelial ovarian cancer
    Sorensen, Sarah Mejer
    Hogdall, Claus
    Mosgaard, Berit Jul
    Dalgaard, Maya Isabella Riise
    Jensen, Mai Partridge
    Fuglsang, Katrine
    Schnack, Tine Henrichsen
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2022, 101 (03) : 334 - 343
  • [23] Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?
    Trope, Claes G.
    Elstrand, Mari B.
    Sandstad, Berit
    Davidson, Ben
    Oksefjell, Halldis
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (14) : 2146 - 2154
  • [24] Interval debulking surgery for advanced epithelial ovarian cancer
    Tangjitgamol, Siriwan
    Manusirivithaya, Sumonmal
    Laopaiboon, Malinee
    Lumbiganon, Pisake
    Bryant, Andrew
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (01):
  • [25] Interval debulking surgery for advanced epithelial ovarian cancer
    Tangjitgamol, Siriwan
    Manusirivithaya, Sumonmal
    Laopaiboon, Malinee
    Lumbiganon, Pisake
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (01):
  • [26] Interval debulking surgery for advanced epithelial ovarian cancer
    Tangjitgamol, Siriwan
    Manusirivithaya, Sumonmal
    Laopaiboon, Malinee
    Lumbiganon, Pisake
    Bryant, Andrew
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (04):
  • [27] Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer: GOTIC-019 study
    Nagao, Shoji
    Tamura, Jun
    Shibutani, Takashi
    Miwa, Maiko
    Kato, Tomoyasu
    Shikama, Ayumi
    Takei, Yuji
    Kamiya, Natsuko
    Inoue, Naoki
    Nakamura, Kazuto
    Inoue, Aya
    Yamamoto, Koji
    Fujiwara, Keiichi
    Suzuki, Mitsuaki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2023, 28 (06) : 804 - 815
  • [28] Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)
    Fagotti, Anna
    Ferrandina, Maria Gabriella
    Vizzielli, Giuseppe
    Pasciuto, Tina
    Fanfani, Francesco
    Gallotta, Valerio
    Margariti, Pasquale Alessandro
    Chiantera, Vito
    Costantini, Barbara
    Gueli Alletti, Salvatore
    Cosentino, Francesco
    Scambia, Giovanni
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (11) : 1657 - 1664
  • [29] Impact of interval from primary cytoreductive surgery to initiation of adjuvant chemotherapy in advanced epithelial ovarian cancer
    Lee, Yoo-Young
    Lee, Jeong-Won
    Lu, Lin
    Xu, Wei
    Kollara, Alexandra
    Brown, Theodore
    Heo, Eun-Jin
    May, Taymaa
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2018, 143 (03) : 325 - 332
  • [30] Interval debulking surgery for advanced epithelial ovarian cancer: A Cochrane systematic review
    Tangjitgamol, Siriwan
    Manusirivithaya, Sumonmal
    Laopaiboon, Malinee
    Lumbiganon, Pisake
    GYNECOLOGIC ONCOLOGY, 2009, 112 (01) : 257 - 264